Eli Lilly Backs Absci's AI-Designed Endometriosis Antibody ABS-201
Start here
Eli Lilly is investing in Absci's ABS-201, a generative AI-designed anti-prolactin receptor antibody intended to treat endometriosis by modifying its underlying pathogenesis rather than only its symptoms. The drug blocks prolactin receptors, a mechanism aimed at the disease's root biology. The backing comes through a $100 million financing for Absci that includes a $40 million strategic investment from Lilly. Phase II trials of ABS-201 are expected to begin in the fourth quarter of 2026. The move fits Lilly's stated strategic shift toward women's health, funded by profits from its GLP-1 drugs. Whether ABS-201's mechanism translates into clinical benefit remains untested until the trials read out.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- reddit.comPickEli Lilly invests in women's health, backing Absci's ABS-201 drug designed to treat endometriosis by modifying its underlying pathogenesis.
Eli Lilly is backing Absci's ABS-201, a generative AI-designed anti-prolactin receptor antibody for endometriosis, through a $100 million financing that includes a $40 million strategic investment from Lilly. ABS-201 is designed to block prolactin receptors to modify the underlying pathogenesis of endometriosis, and Phase II trials are expected to start in Q4 2026. The support fits Lilly's stated shift toward women's health, funded by GLP-1 profits.
Heat trend for this story
Not enough continuous observation yet to draw a trend.